Diovan Clinical Trials
Here are the 6 most popular medical studies for diovan
Angiotensin-II Receptor Antagonist and Direct Renin Inhibitor
Aliskiren + Valsartan for Diabetes
Recruiting5 awardsPhase 4
Baltimore, Maryland
People with both hypertension and diabetes have a higher chance of developing heart and arterial problems that could be reduced with anti-coagulant therapy. Valsartan (Diovan), an FDA approved angiotensin-II receptor antagonist (blocker) clinically indicated for the treatment of essential hypertension is known to inhibit platelet activity in both an in vitro and ex vivo setting. Aliskiren (Tekturna) is a recently FDA-approved potent direct renin inhibitor which is also an effective anti-hypertensive agent in patients with mild-to-moderate hypertension and which, in vitro, modulates antithrombin III in plasma. Therefore, in addition to being clinically approved anti-hypertensive medications, combining these two agents will potentially target both primary hemostasis (platelets) and anticoagulant (antithrombin-III is a cornerstone substrate for heparin) properties to exert their anti-thrombotic efficacy simultaneously. This combination strategy may not only improve hypertension management, but also improve vascular outcomes in high-risk diabetic population via favorable effects on anti-thrombotic activity. Importantly, there have been no significant additional safety concerns of using the combination of aliskiren and valsartan. The investigators hypothesis is that valsartan 160 mg/daily in combination with aliskiren 150-300 mg/daily for 4 weeks will favorably affect blood levels of platelet/coagulation/fibrinolytic biomarkers (ie, diminish platelet activity, and enhance antithrombin III potency) when compared with monotherapy with aliskiren 150mg/daily in hypertensive patients with type 2 diabetes mellitus.
Angiotensin Receptor Neprilysin Inhibitor
Sacubitril/valsartan +5 More for Congestive Heart Failure
Recruiting3 awardsPhase 4
Huntsville, Alabama
This trial is being done to see which treatment options work best for people with congestive heart failure. They will be looking at different treatments like observing the patients, giving them diuretic medicine, or
Popular filter options for diovan trials
Clinical Trials With No Placebo
View 20 medical studies that do not have a placebo group.
Angiotensin Receptor Neprilysin Inhibitor
Sacubitril/Valsartan for Heart Failure
Recruiting3 awards2 criteria
Toronto, Ontario
The purpose of this study is to compare the changes in B-type Natriuretic Peptide (BNP) and amino-terminal fragment of proBNP (NT-proBNP) in outpatients managed in the heart failure (HF) clinic initiated on the Angiotensin Receptor Neprilysin Inhibitor (Entresto) and directly compare the prognostic values of BNP and NT-proBNP in patients admitted with acute decompensated HF.
Angiotensin Receptor Blocker/Neprilysin Inhibitor
Combination Blood Pressure Therapy for High Blood Pressure
Recruiting3 awardsPhase 4
Nashville, Tennessee
This trial is testing if a two-drug combination can increase blood flow more than one of the drugs can on its own, and if a third drug can interact with the first two to also increase blood flow.
Angiotensin II Receptor Blocker, COX-2 Inhibitor, Biguanide
Valsartan + Celecoxib + Metformin for Type 2 Diabetes
Recruiting3 awardsPhase 1 & 2
Albany, New York
This trial is evaluating the safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise. The objective is to assess the effect of RK-01 on hemoglobin A1c (HbA1c) levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl X
Vascular Function in Pulmonary Arterial Hypertension
Recruiting2 awardsPhase 1
Salt Lake City, Utah
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
View More Diovan Trials
See another 5 medical studies focused on diovan.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.